Novo Nordisk's next generation weight loss drug CagriSema matches Lilly's Zepbound in major trial, but doesn't surpass it CNN Once weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double blind, placebo controlled and active controlled, dose finding phase 2 trial The Lancet Novo Nordisk's stock drops despite CagriSema hitting goal of Phase III trial Clinical Trials Arena Two Weeks on GHK CU by Rory Uphold The Ladies Room